Navigation Links
Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinson's Congress
Date:10/2/2013

roups: placebo, 260 mg ADS-5102, 340 mg ADS-5102 and 420 mg ADS-5102.  Both the 340 mg and 420 mg ADS-5102 dose levels significantly reduced LID as measured by the change in Unified Dyskinesia Rating Scale (UDysRS) total score over eight weeks versus placebo, meeting the primary endpoint for the clinical study.  Of note, the reduction in LID was seen at two weeks following the first dose of study medication.  At week 8, the ON time without troublesome dyskinesia as measured by patient diaries was 11.0 hours, 11.5 hours, and 12.1 hours for the 260 mg, 340 mg, and 420 mg dose levels, respectively, compared to 8.0 hours for placebo.  These findings were statistically significant, demonstrating an increase of about 3 hours over placebo compared to baseline values.  ADS-5102 also demonstrated statistically significant functional improvement in dyskinesia as assessed by the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV, a measure of the degree of impact that dyskinesia has on the patient's daily function in terms of activities and social interactions.

Treatment with ADS-5102 did not result in worsening of PD, as measured by the MDS-UPDRS combined score (Parts I, II and III).  The adverse events reported in this study were typically mild to moderate in severity and consistent with Parkinson's disease and the known amantadine safety profile.  There was no difference from placebo in the incidence of sleep-related adverse events.

Data from the Phase 2/3 study were presented today in a poster entitled "Safety and Efficacy of ADS-5102 in Levodopa-Induced Dyskinesia (EASED Study)" (Abstract #1311.00) at 11:30 am ET at the World Parkinson's Congress in Montreal, Canada.  The poster has also been selected for a "Guided Poster Tour" between 5:15-6:45 pm ET.  Additional details of the EASED study results may be found on the Adamas website.

About the EASED
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
2. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
3. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
4. Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Sep. 03, 2015 Research ... of the "Investigation Report on China,s Raloxifene Market, ... to the statistics, over 200 million people suffer from ... above in China , 50% have ... 30%-50% among women aged 60 and above. Raloxifene ...
(Date:9/3/2015)... -- China,s startup business ExtantFuture ... wearable medical device that can continuously monitor the fetal ... guidance for pregnant women. The device will debut on ... measures 4 centimeters in diameter, is as thin as ... an Apple earphone cord. The small and compact device ...
(Date:9/3/2015)... Sept. 3, 2015 HeartWare International, Inc ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... its President and Chief Executive Officer, Doug Godshall ... Fargo Healthcare Conference at 8:50 a.m. ET on Wednesday, ... 2015 at The Hyatt Regency, Boston ...
Breaking Medicine Technology:Investigation Report on China's Raloxifene Market, 2015-2019 2Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2
... 28 Parents may be giving their children ... research being presented this week at Research Forum ... American College of Emergency Physicians.  Two studies are ... Medication Dosing Cups Are Inaccurate" and "Do Parents ...
... YORK, Sept. 27 Pfizer Inc. announced today ... trial evaluating SUTENT® (sunitinib malate) in combination with ... (CRPC) that had progressed despite treatment with a ... an independent Data Monitoring Committee (DMC) found that ...
Cached Medicine Technology:Warnings Re: Over-the-Counter Medication for Children: Less is More 2Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer 2Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer 3Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer 4
(Date:9/3/2015)... VA (PRWEB) , ... September 03, 2015 , ... ... the Spouse/Caregiver Scholarship applications are open for spring 2016. Scholarships are awarded two ... members. Hope For The Warriors® is a national nonprofit dedicated to restoring a ...
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional ... her debut book, “Stop Wasting Your Time Blaming Others for Your Life.” , ... guide to overcoming life’s obstacles by taking full responsibility for one’s life shares ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... comprehensive eating disorder treatment for adults and adolescents struggling with anorexia, bulimia, ... has joined the medical treatment team. As a Staff Psychiatrist, Dr. Calinoiu ...
(Date:9/3/2015)... ... 2015 , ... As a result of the Patient Protection ... insurance plans, more employers are moving to a self-funded model for pharmacy plans, ... United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the nation’s largest ...
(Date:9/3/2015)... ... 03, 2015 , ... ProScrub is a set of automated tools that allow ... custom speed effects without the use of keyframes. Utilize ProScrub's powerful sliders to ... are perfect complements to energetic video productions. ProScrub is a Final Cut ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... , , SAN RAMON, Calif., ... who plays Dwight Schrute on NBC,s hit show The Office, ... night, August 15, at the home of Gouya and Payam Zamani, ... Mona Foundation, a non-profit organization that supports social and economic development ...
... juice to combat urinary tract infections is ,unsatisfactory and ... day..." Not all medical problems require a state-of-the-art solution, ... from the corner shop could treat a widespread and ... touted as a simple solution for urinary tract infections, ...
... , , , ... a leading national law firm in the fight against mesothelioma and ... foremost trial attorneys in the country, has joined the firm as ... of asbestos cancer cases since the late 1970s. He has successfully ...
... , , , ... sanofi-aventis U.S. announced today that the U.S. Food and Drug ... six months and older for the relief of symptoms of ... hives) and for children age two years and older for ...
... Avacor ( ) P r oducts LLC ... in the hair re-growth industry, has recently teamed up with two charitable organizations, ... ), and Team Continuum ( http://www.teamcontinuum.net ). ... fighting cancer as well as to help find new ways to fight this prolific ...
... , ST. LOUIS, Aug. 24 ... the herbicide Atrazine have attorney and clean water advocate Steve ... transparency and accountability for the herbicide,s manufacturers. , , ... in the New York Times and the Peoria Journal Star ...
Cached Medicine News:Health News:Rainn Wilson ('Dwight' on The Office) Joins Reply.com at Fundraiser for Mona Foundation 2Health News:Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as 'Of Counsel' 2Health News:Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as 'Of Counsel' 3Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 2Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 3Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 4Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 5Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 6Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 7Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 8Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 9Health News:FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 10Health News:Avacor(R), a Leader in Hair Regrowth, Announces Charities of Choice: Team Continuum and City of Hope 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Severe revision options for the knee and hip...
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: